Posted: 12 November 2014. Updated: 12 November 2014

Pharmaceutical giant AstraZeneca, who recently fended off a takeover attempt by American company Pfizer, has submitted plans to build a £330 million global R&D centre and corporate headquarters in Cambridge. The plans would see the company relocate from Alderley Edge in Cheshire and is claimed will bring 2,000 jobs to the city.
The NAVS is opposing the plans on the grounds that animal research facilities will be on site and we are concerned that so little information has been provided regarding the housing and use of animals AstraZeneca use a huge number of animals for research each year - more than 280,000 in 2013 - but there is no information provided in the application as to how the welfare of the animals will be ensured nor how the company intends to reduce, and work towards ending, its use of animals in research in line with the aims of the EU Directive governing animal experiments. This is despite the application running to hundreds of pages and containing detailed information on other aspects.
The EU Directive, which the UK has passed into law places a duty on the Government to “contribute to the development and validation of alternative approaches which could provide the same or higher levels of information as those obtained in procedures using animals.” The market for alternative products and services such as computer modelling and advanced tissue/cell cultures is worth about the same as the contract research testing industry and is projected to double by 2017.
With a wide range of advanced non-animal research methods at AstraZeneca“s disposal, and an operating profit of $5,753 million for the first nine months of 2014 alone, the NAVS hopes that AstraZeneca will commit to investing in this area, providing an economic advantage to Cambridge and enabling outdated animal testing to continue to be replaced.
The NAVS has previously campaigned for AstraZeneca to rehome beagles from kennels in Sweden which were earmarked for closure in a bid to save more than £1 billion. Despite having already rehomed some of the animals with staff, AstraZeneca ignored calls from the NAVS and our supporters, together with a coalition of 20 groups, and sent the dogs to the company“s research facility at Alderley Edge. It is not clear from the planning application being considered whether beagles will be housed at the proposed new facility.